Stock AnalizCryoport, Inc. CYRX
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Cryoport, Inc. (CYRX) is a healthcare company listed in the US with a market value of about $1.0B. In the twelve months to September 30, 2026 it had revenue of $192M and net income of -$41M, a net margin of -21.5%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 17% a year, a 5-year average ROIC of -10%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 94% below the current price.
Score: 1.4 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- ROE above 15%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $192M | $176M | $157M | $169M | $237M | $223M | $79M | $34M | $20M | $12M | $8M |
| Net income | -$41M | $78M | -$115M | -$100M | -$37M | -$276M | -$33M | -$18M | -$10M | -$8M | -$13M |
| Free cash flow | -$20M | -$25M | -$34M | -$40M | -$24M | -$16M | -$24M | -$7M | -$6M | -$5M | -$7M |
| EPS (diluted) | $-0.98 | $1.40 | $-2.49 | $-2.21 | $-0.93 | $-6.18 | $-1.94 | $-0.55 | $-0.34 | $-0.34 | $-0.93 |
| Net margin | -21.5% | 44.4% | -73.2% | -59.1% | -15.7% | -123.8% | -41.5% | -54.0% | -48.7% | -66.1% | -170.8% |
| ROIC | — | -5.3% | -21.2% | -15.1% | -4.3% | -2.1% | -5.9% | -10.7% | -12.3% | -34.9% | -121.9% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 9 analysts is $22.33, 12% above the current price; targets range from $18.00 to $28.00; the consensus rating is “Strong buy”; expected EPS is $-0.79 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Cryoport stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 94% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Cryoport pay a dividend?
Not currently.
Is Cryoport a good stock to buy?
We do not give buy or sell advice. Cryoport scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.